News Could an AI-powered eye test spot dementia early on? A UK alliance between data scientists, clinical researchers, and community opticians hopes to develop an AI to predict dementia during an eye test.
News Two more biotechs join IPO waiting list Odyssey and Sionna have filed to carry out IPOs on the Nasdaq, following after Metsera and Maze which filed earlier in January.
News Large study points to benefits - and risks - of GLP-1 drugs The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.
News Sun Pharma unit poised to buy Canadian biotech Antibe Sun Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe, a developer of drugs for pain and inflammation.
News High-dose semaglutide ramps up weight loss, says Novo Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.
News Boehringer drug for brain fog in schizophrenia fails trial Boehringer Ingelheim's bid to develop the first drug therapy for impaired cognitive function in schizophrenia looks like it has reached an end.
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.